Octant sets sail for new era of drug discovery with $80M funding, Bristol Myers partnership

Study will evaluate the safety, tolerability and pharmacokinetics (PK) of OCT-980 in healthy volunteers

Initiation of the study marks Octant’s transition to a clinical-stage company